Trial Profile
The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Amyloidosis
- Focus Diagnostic use
- 06 Jan 2020 Status changed from recruiting to discontinued.
- 13 Dec 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 13 Dec 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.